Avedro, Inc., an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations. Its Avedro Corneal Remodeling platform treats corneal ectatic disorders and corrects refractive conditions; and KXL system in combination with Photrexa drug formulations used for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro sells its products through a direct sales force in the United States and through medical device distributors internationally. The company was formerly known as ThermalVision, Inc. and changed its name to Avedro, Inc. in October 2005. Avedro, Inc. was incorporated in 2002 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone781-768-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.67 million
Profitability
Miscellaneous
Employees122
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable
Avedro (NASDAQ:AVDR) Frequently Asked Questions
What is Avedro's stock symbol?
Avedro trades on the NASDAQ under the ticker symbol "AVDR."
How were Avedro's earnings last quarter?
Avedro Inc (NASDAQ:AVDR) posted its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.02. The business had revenue of $11.05 million for the quarter, compared to analysts' expectations of $9.96 million. Avedro had a negative return on equity of 162.76% and a negative net margin of 81.59%. View Avedro's Earnings History.
When is Avedro's next earnings date?
What price target have analysts set for AVDR?
6 brokers have issued 1-year price targets for Avedro's shares. Their forecasts range from $21.00 to $27.00. On average, they anticipate Avedro's share price to reach $23.60 in the next twelve months. This suggests a possible upside of 2.7% from the stock's current price. View Analyst Price Targets for Avedro.
What is the consensus analysts' recommendation for Avedro?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avedro in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Avedro.
Has Avedro been receiving favorable news coverage?
Press coverage about AVDR stock has been trending somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avedro earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Avedro.
Who are some of Avedro's key competitors?
Some companies that are related to Avedro include Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Alder Biopharmaceuticals (ALDR), Esperion Therapeutics (ESPR), Amneal Pharmaceuticals (AMRX), Corcept Therapeutics (CORT), Innoviva (INVA), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Nabriva Therapeutics (NBRV), Endo International (ENDP), TG Therapeutics (TGTX) and Madrigal Pharmaceuticals (MDGL).
What other stocks do shareholders of Avedro own?
Who are Avedro's key executives?
Avedro's management team includes the folowing people:
- Dr. Reza Zadno, Pres, CEO & Director (Age 64)
- Mr. Thomas E. Griffin, Chief Financial Officer (Age 56)
- Dr. Rajesh K. Rajpal, Chief Medical Officer & Member of Advisory Board (Age 56)
- Mr. James Schuermann, Chief Bus. Officer (Age 51)
- Mr. Marc Friedman, Chief Scientific Officer
When did Avedro IPO?
(AVDR) raised $75 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Cowen, Guggenheim Securities and SVB Leerink were co-managers.
How do I buy shares of Avedro?
Shares of AVDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Avedro's stock price today?
One share of AVDR stock can currently be purchased for approximately $22.99.
How big of a company is Avedro?
Avedro has a market capitalization of $402.78 million and generates $27.67 million in revenue each year. The company earns $-25,120,000.00 in net income (profit) each year or ($17.97) on an earnings per share basis. Avedro employs 122 workers across the globe.View Additional Information About Avedro.
What is Avedro's official website?
How can I contact Avedro?
Avedro's mailing address is 201 JONES ROAD, WALTHAM MA, 02451. The company can be reached via phone at 781-768-3400 or via email at [email protected]
MarketBeat Community Rating for Avedro (NASDAQ AVDR)
MarketBeat's community ratings are surveys of what our community members think about Avedro and other stocks. Vote "Outperform" if you believe AVDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDR will underperform the S&P 500 over the long term. You may vote once every thirty days.
